Please see annexed enclosure.

July 30, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam, Sub: Transcript of the Q1 FY '27 Results Conference Call hosted on July 24, 2026 Pursuant to Regulation 30 & 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and with reference to our results conference call intimation dated July 09, 2026, please be informed that the results conference call for Q1 FY27 was hosted on July 24, 2026 and the transcript of the conference call is enclosed herewith. This is for your information and records. Thanking You Yours faithfully, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer Encl: A/a “Laurus Labs Limited Q1 FY27 Earnings Conference Call” July 24, 2026 MANAGEMENT: DR. SATYANARAYANA CHAVA – FOUNDER AND CHIEF EXECUTIVE OFFICER – LAURUS LABS LIMITED MR. V. V. RAVI KUMAR – EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER – LAURUS LABS LIMITED MR. KRISHNA CHAITANYA CHAVA – EXECUTIVE DIRECTOR, HEAD CDMO – LAURUS LABS LIMITED MS. SOUMYA CHAVA – EXECUTIVE DIRECTOR GENERICS AND COMMERICAL – LAURUS LABS LIMITED MR. VIVEK KUMAR –AVP – INVESTOR RELATIONS – LAURUS LABS LIMITED MODERATOR: MR. NITIN AGARWAL – DAM CAPITAL ADVISORS Page 1 of 17 Laurus Labs Limited July 24, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Laurus Labs Q1 FY '27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Nitin Agarwal. Thank you, and over to you, sir. Nitin Agarwal: Thank you, Bharat. Good evening, everyone, and a very warm welcome to Laurus Labs Q1 F '27 Earnings Call hosted by DAM Capital Advisors Limited. On the call today, we have representing Laurus Labs management: Dr. Satyanarayana Chava, Founder and CEO; Mr. V. V. Ravi Kumar, Executive Director and CFO; Mr. Krishna Chaitanya Chava, ED, Head CDMO; Ms. Soumya Chava, ED, Generics and Commercial; and Mr. Vivek Kumar, AVP, Investor Relations. Before we proceed, I would like you to remind you that some of the statements made during the call today could be forward-looking in nature, and a safe harbor statement to this effect has been included in the press release that has been shared on the company's website. I hand over the call to Dr. Chava to make the opening comments, and then we'll open the floor for questions. Please go ahead, sir. Satyanarayana Chava: Thanks for the introduction. Good afternoon to all our stakeholders. We continue to make steady progress and a strong demand environment for multiple complex technology platforms and integrated manufacturing capabilities. We reported significant acceleration in our CDMO business, maintained sustained momentum in affordable medicine portfolio, and continue to show tangible advancement in our mid- and late-stage commercial projects with global innovators. We are executing well on our transformation strategy with a clear focus and determination to realize the near- to medium-term opportunities. At the same time, we continue investing in capacity readiness to better meet our client needs, new technologies, emerging and complex modalities like peptides, ADCs, gene therapy, etcetera, to seize the next wave of business opportunities that will positively drive future value creation for all stakeholders. Moving on to financial results. Laurus maintained its strong growth momentum, delivering highest quarterly revenue, EBITDA and profits during the first quarter. The company's revenues were INR2,026 crores, showing a 29% growth. This was mainly driven by growing contribution of commercial supplies in CDMO segment and continued strength in affordable medicine portfolio. Gross margins were also very healthy and maintained around 62.7% and EBITDA margins further expanded over previous quarter by 7 percentage points to 31.8%. Our product mix within the business divisions operating leverage continued to do well, supporting healthy margins overall. We also achieved several milestones in our operations. Page 2 of 17 Laurus Labs Limited July 24, 2026 The first one is we signed a development and commercial agreement with Aarvik Therapeutics for 2 ADC molecules for India markets. Those are in the clinical stage. We have onboarded a big pharma client with significant opportunities ahead of us. The third one, the final handover of 500-plus acres of land parcel from AP government is in the final stages now. I would like to thank our dedicated team for their relentless effort and strong progress we are achieving now. I would request Ms. Krishna Chava to share key updates on our CDMO segment. Krishna Chava: Yes. Thank you, sir. Within the CDMO side, the division has continued to deliver strong operational execution in Q1, reporting a growth of 69% with the sales of INR835 crores on the small molecule side. This is mainly driven by acceleration in the late-stage clinical and commercial deliveries of the programs for multiple global partners. We continue to see good and encouraging progress across both Human Health and Animal Health businesses, both on volume ramp-ups with existing portfolios and also new potential customer engagements. As we continue to strengthen capabilities of our CDMO platform, we are constantly enhancing the service efficiency and also conversion of the opportunities at various different clinical stages, reflecting client trust in our technical and commercial capabilities. Continued investment into capacity creation at our Vizag site and also advancing quite well on the commercial scale peptide capacities based on customer demand. I would say with customers' ongoing demand for enabling services, our strong CDMO business model and the management execution in line with which the company is confident to sustain a very healthy business growth. Now moving on to the Laurus Bio side of things. Bio division reported a Q1 sales of about INR35 crores, which is about 21% growth year-on-year, which is broadly in line with our expectation. The growth is supported by customer revenue diversification and also continued pipeline progress on some of the larger global accounts, both in the animal origin-free space and also in the CDMO side. We have continued to demonstrate significant value add through the expanded application and capabilities, especially in the enzymatic and biocatalysis platform across various different clinical phases, further deepening long-term customer partnerships. Construction work for the commercial scale fermentation facility and strengthening of our downstream processing infrastructure is progressing in line with the plan, and we expect Phase 1 of this capacity, which is a little over 400 kiloliters is expected to be operational towards the end of this year. Thank you. Satyanarayana Chava: Now, I would like to request Ms. Soumya Chava to share the key updates on our Affordable Medicines division. Soumya Chava: Thank you. Our Affordable Medicine division delivered a strong quarter 1 performance with revenue reaching to INR1,156 crores, which is an increase of 10% year-on-year. Our growth Page 3 of 17 Laurus Labs Limited July 24, 2026 was driven by higher volumes across our established portfolio, including ARVs and onco where we continue to maintain our market leadership. Our recently launched products in the developed markets also sustained their strong momentum. Operational execution remains robust, supported by consistent supply reliability, improving efficiencies and greater resilience across [Showing first 8,000 characters — download PDF for full document]